Along these lines, many biomarkers targeted treatments are in clinical development for patients with Th2 immune response: anti-IL-4/IL-13, anti-IL-4, anti-IL-5, anti-IgE antibodies, and CRTh2 (chemoattractant receptor-homologous molecule expressed on Th2 cell antagonists) (15–17), although in the latter case, two recently conducted large Phase 2 studies with CRTh2 antagonists have either failed to demonstrate significant efficacy in clinical endpoints compared to placebo (18) or showed a similar degree of improvement with the active control (19) in patients with atopic/allergic asthma. The gene discussed is PTGDR2; the disease is allergic asthma.